WELTZIEN LOURDES 4
4 · MERIDIAN BIOSCIENCE INC · Filed Feb 17, 2022
Insider Transaction Report
Form 4
WELTZIEN LOURDES
EVP, Life Science
Transactions
- Sale
Common Stock
2022-02-15$25.60/sh−20,000$511,912→ 83,048 total - Exercise/Conversion
Stock Options (Right to Buy)
2022-02-15−12,500→ 0 totalExercise: $14.65Exp: 2027-11-08→ Common Stock (12,500 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2022-02-15−7,500→ 2,500 totalExercise: $14.30Exp: 2028-04-24→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2022-02-15$14.30/sh+7,500$107,250→ 103,048 total - Exercise/Conversion
Common Stock
2022-02-15$14.65/sh+12,500$183,125→ 95,548 total
Footnotes (3)
- [F1]The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $25.29 to $26.07. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
- [F2]These non-qualified options were awarded under the 2012 Stock Incentive Plan and cliff vested in full on November 15, 2021.
- [F3]These options were awarded under the 2012 Stock Incentive Plan and vest in four equal installments from the date of grant until fully vested on April 24, 2022.